Written by Rina Brown-Ono, LMHC
Note: This blog refers to menstruating individuals of all gender identities. For readability, the term “women” will be used throughout to refer to menstruating individuals of all gender identities. Although these patterns are more frequently documented among women, it is important to recognize that they are not exclusive to the female population. Men with ADHD may also experience similar challenges, including masking, being misunderstood, or receiving a delayed diagnosis.
Attention-deficit/hyperactivity disorder (ADHD) affects individuals of all gender identities and can influence attention, hyperactivity, and impulsivity throughout their lives. Recent research and clinical observations suggest that women are more likely to be underdiagnosed or misdiagnosed and often receive an ADHD diagnosis later in life. This blog explores the unique experiences and challenges of living with ADHD as a woman, including how symptoms may present differently and how hormonal changes influence ADHD symptoms.
Figuring out the Diagnosis
It is well-known that females under the age of 12 are four times less likely to receive an ADHD diagnosis compared to their male peers (Wynchank et al., 2026). Questions arise about the idea that ADHD is a male-dominated neurotype. Recent ideas about ADHD suggest that the diagnostic disparity may stem from several factors, including a lack of awareness about how ADHD presents in females among professionals, differences in symptom presentation, male-centered diagnostic criteria, and biological factors such as hormonal fluctuations in females.
Symptom masking is one explanation for the lack of balance in ADHD diagnosis across gender. Societal expectations and modeling of behavior in females may contribute to symptoms being less obvious. Cultural and social norms that result in less hyperactive behavior in females, potentially contributes to missed diagnosis, as well as higher rates of anxiety and depression (Wynchank et al., 2026). Indeed, ADHD research has historically focused primarily on men, and researchers suggest this is partly due to concerns about reproductive cycles and hormonal fluctuations in women (Findeis and Straub, 2025). Consequently, existing diagnostic criteria may reflect symptom presentations that are more commonly recognized in males, potentially overlooking how ADHD manifests in women.
Consequences of Delayed or Missed Diagnosis
Delayed or missed ADHD diagnoses can have significant consequences for women, affecting various aspects of their lives. These consequences may include an increased risk of teenage pregnancy, risky sexual behaviors, self-harm, eating disorders, relationship difficulties, mental health challenges, and lower self-confidence and self-esteem (Kooij et al., 2025). Furthermore, Findeis and Straub (2025) highlighted that women with ADHD may face a greater likelihood of involvement in the criminal justice system than men with ADHD.
Findeis and Straub (2025) also noted that women with ADHD may experience greater difficulties with social functioning, as well as more pronounced affective and anxiety symptoms. These challenges may contribute to mood fluctuations and difficulties with emotional regulation, potentially affecting their daily lives and interpersonal relationships.Women with ADHD may also be more likely to engage in risky behaviors, even after receiving a diagnosis (Young et al., 2020). These behaviors can include substance use, risky sexual behaviors, and an increased risk of motor vehicle accidents.
Medication management is the first-line treatment for ADHD and research suggests that medication treatment for ADHD in women is associated with a reduced risk of emergency department visits related to motor vehicle accidents and certain criminal outcomes (Findeis & Straub, 2025). These findings highlight the potential benefits of medication in managing ADHD symptoms and reducing some associated risks.
The Role of Hormones
New research has explored the role of hormone fluctuations that can influence ADHD symptoms and potentially affect the effectiveness of ADHD medication. According to Osianlis et al. (2025), female sex hormones, particularly estrogen and progesterone, influence neurotransmitter systems involving serotonin, dopamine, and noradrenaline, which also play important roles in thinking and behavior.
Dopamine, in particular, is involved in executive functioning, including attention, planning, and impulse control. ADHD is associated with differences in dopamine signaling and regulating in the brain, which may contribute to difficulties with attention, motivation, and executive functioning. Estrogen also influences dopamine activity in the brain. Therefore, when estrogen levels decline or fluctuate, women with ADHD may experience worsening symptoms (Findeis & Straub, 2025).
Though the research is still emerging, new evidence suggests that certain life stages and phases of the menstrual cycle, including puberty, perimenopause, menopause, and specific phases of the menstrual cycle, may be associated with changes in ADHD symptoms. In addition, there is considerable overlap between ADHD symptoms and those associated with premenstrual syndrome (PMS), which may make symptoms recognition and management more challenging for some women.
Understanding how ADHD affects women is essential to improving awareness, diagnosis, and treatment. Differences in symptom presentation, societal expectations, and hormonal fluctuations can create unique challenges throughout a woman's life. Early recognition, appropriate treatment, and greater awareness among healthcare professionals can help women with ADHD better understand and manage their symptoms. Ultimately, increasing awareness of ADHD in women is an important step toward reducing stigma and ensuring that everyone receives the support they need to thrive.
References
Wynchank et al. (2025). Practical tools for female-specific ADHD: The impact of hormonal fluctuations in clinical practice and from the literature. European Psychiatry. 69(1). https://doi.org/10.1192/j.eurpsy.2025.10120.
Findeis, H. & Straub, M. (2025). The effects of psychostimulants in menstruating women with ADHD – A gender health gap in ADHD treatment? Progress in Neuropsychopharmacology & Biological Psychiatry. https://doi.org/10.1016/j.pnpbp.2025.111261.
Osianilis, E. et al. (2025). ADHD and sex hormones in females: A systemic review. Jornal of Attention Disorders. 29(9). 706-723. https://doi.org/10.1177/10870547251332319.
Kooij, J. et al., (2025). Research advances and future directions in female ADHD: The lifelong interplay of hormonal fluctuations with mood, cognition, and disease. Frontiers in Global Women’s Health. https://doi.org/10.3389/fgwh.2025.1613628.
Young, S. et al. (2020). Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/hyperactivity disorder in girls and women. BMC Psychiatry. https://doi.org/10.1186/s12888-020-02707-9.
